FTSE 100 news / Companies and sectors / Smith & Nephew
Smith & Nephew news analysis
Smith & Nephew (LSE: SN) is in the FTSE 100. 19 of the last 21 days had relevant coverage.
Latest: Tuesday 20 October 2026
−0.7 from 3 relevant stories. Coverage centred on Smith & Nephew's struggle against Stryker in knee replacement robotics, which weighs on the tone. A UBS note pointing to attractive risk/reward ahead of third-quarter results offset some of that.
Tone over time
Coverage of Smith & Nephew improved between 30 September 2026 and 20 October 2026
Daily news tone, from −10 (clearly bad) to +10 (clearly good). Gaps are days with no relevant stories.
Tone rose 86% from −5 to −1 between 30 Sep and 20 Oct. Its low was −6 in 19 Oct.
- 11
- 22
- 33
10 days of 19 had fewer than 3 relevant stories, so those points are thin evidence. Numbered markers are the days with the strongest single headline (key below). This is the tone of coverage, not a share price.Source: MarketFrame news analysis
| day | Tone |
|---|---|
| 30 Sep | −5 |
| 1 Oct | 2 |
| 2 Oct | −5 |
| 3 Oct | 1 |
| 4 Oct | 2 |
| 5 Oct | −1 |
| 6 Oct | 4 |
| 7 Oct | 8 |
| 8 Oct | 2 |
| 9 Oct | 7 |
| 10 Oct | 1 |
| 11 Oct | – |
| 12 Oct | 7 |
| 13 Oct | 2 |
| 14 Oct | 4 |
| 15 Oct | −2 |
| 16 Oct | 4 |
| 17 Oct | 1 |
| 18 Oct | – |
| 19 Oct | −6 |
| 20 Oct | −1 |
Day by day
| Day | Tone | Stories | What the coverage was about |
|---|---|---|---|
| Tuesday 20 October 2026 | −0.7 | 3 | Coverage centred on Smith & Nephew's struggle against Stryker in knee replacement robotics, which weighs on the tone. |
| Monday 19 October 2026 | −6.3 | 2 | Coverage was led by Smith & Nephew cutting its sales outlook, which weighs on the tone. |
| Sunday 18 October 2026 | – | 0 | |
| Saturday 17 October 2026 | +1.3 | 1 | Coverage was a single piece looking at Smith & Nephew's outlook and dividend. |
| Friday 16 October 2026 | +4.0 | 5 | Coverage was mainly about a 4.3% share price gain, the European launch of CARTIHEAL and an executive's comments on Latin America. |
| Thursday 15 October 2026 | −2.3 | 3 | Coverage centred on Smith & Nephew cutting its sales outlook, which put the stock under scrutiny. |
| Wednesday 14 October 2026 | +4.0 | 2 | Coverage centred on a US product launch for pressure ulcer devices and a discussion of whether the company's American knee business can recover once Landmark reaches surgeons. |
| Tuesday 13 October 2026 | +1.7 | 3 | Coverage was mixed: the Xodus Medical acquisition to broaden its portfolio was positive, while analysts trimmed their price target and commentary asked whether the shares can rebound ahead of the next trading update. |
| Monday 12 October 2026 | +7.0 | 1 | Coverage focused on Smith & Nephew's launch of a cartilage implant in Europe, which is described as strengthening its sports medicine growth. |
| Sunday 11 October 2026 | – | 0 | |
| Saturday 10 October 2026 | +0.5 | 1 | Coverage was limited to a note that the shares were trading without their dividend. |
| Friday 9 October 2026 | +6.8 | 4 | Coverage centred on the European launch of the CARTIHEAL cartilage implant, which reads as a positive step for its sports medicine business. |
| Thursday 8 October 2026 | +2.2 | 2 | Coverage centred on the publication of the company's earnings call transcript and a piece on its joint preservation strategy in Europe. |
| Wednesday 7 October 2026 | +7.5 | 7 | Coverage was mainly about the European launch of the Cartiheal Agili-C cartilage repair implant, which reads as a positive product development. |
| Tuesday 6 October 2026 | +4.0 | 5 | Coverage centred on product news, with regulatory clearance for the LANDMARK knee system and the launch of the EVOS system. |
| Monday 5 October 2026 | −1.3 | 1 | The only relevant coverage concerned Smith & Nephew facing a USD 350 million debt redemption. |
| Sunday 4 October 2026 | +2.0 | 2 | Coverage was light, with a trading-pattern note on the shares and a share price update alongside a showcase of its shoulder technologies. |
| Saturday 3 October 2026 | +1.3 | 1 | Coverage was limited to a single dividend analysis article on Smith & Nephew. |
| Friday 2 October 2026 | −4.7 | 5 | Coverage centred on the shares hitting a 52-week low and trading under pressure despite a new knee system clearance. |
| Thursday 1 October 2026 | +2.0 | 3 | Coverage mixed a new EVOS PELVIC trauma system launch and reported first-half growth of 4.60 percent with a piece on scrutiny over leadership and debt headlines. |
| Wednesday 30 September 2026 | −4.7 | 1 | The only relevant coverage was an analyst downgrade of Smith & Nephew to Add by AlphaValue/Baader Europe, which leans mildly negative. |
Sector: Pharma and healthcare